Deutsche Bank Starts Johnson & Johnson (JNJ) at Hold; Some Upside But Mot Enough
Tweet Send to a Friend
Get Alerts JNJ Hot Sheet
Price: $86.82 -0.45%
Rating Summary:
8 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
8 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade JNJ Now!
Deutsche Bank initiates coverage on Johnson & Johnson (NYSE: JNJ) with a Hold. PT $73.
Deutsche analyst says, "We believe J&J's pharma pipeline is well understood and do not see any major differences between our forecast and consensus. The exit of coronary stents makes sense but may pressure near-term sales and earnings. We are cautious on the pending Synthes deal. The worst is likely behind Consumer OTC as J&J returns products to market but rebating likely required and private labels continue to pressure. Based on a sum-of-the-parts valuation, we see some upside but not enough to warrant a more positive stance given our inline EPS outlook."
"We believe the Consumer OTC business is likely to improve with easy comps and as products come back to market, but higher rebating is likely and private labels will continue to pressure results."
For more ratings news on Johnson & Johnson click here and for the rating history of Johnson & Johnson click here.
Shares of Johnson & Johnson closed at $67.92 yesterday, with a 52 week range of $56.86-$68.05.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Deutsche analyst says, "We believe J&J's pharma pipeline is well understood and do not see any major differences between our forecast and consensus. The exit of coronary stents makes sense but may pressure near-term sales and earnings. We are cautious on the pending Synthes deal. The worst is likely behind Consumer OTC as J&J returns products to market but rebating likely required and private labels continue to pressure. Based on a sum-of-the-parts valuation, we see some upside but not enough to warrant a more positive stance given our inline EPS outlook."
"We believe the Consumer OTC business is likely to improve with easy comps and as products come back to market, but higher rebating is likely and private labels will continue to pressure results."
For more ratings news on Johnson & Johnson click here and for the rating history of Johnson & Johnson click here.
Shares of Johnson & Johnson closed at $67.92 yesterday, with a 52 week range of $56.86-$68.05.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- Janssen Pharma (JNJ) Plans Slew of Filing, Extension Submissions by FY17
- UPDATE: 8x8 Inc. (EGHT) Misses Q4 EPS by 1c
Create E-mail Alert Related Categories
New CoverageRelated Entities
Deutsche Bank, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
